Resistant Hypertension Management

Diuretic Therapy

The American Heart Association recommends adding a thiazide diuretic, such as chlorthalidone 12.5-25mg daily, to the regimen of patients with resistant hypertension, as it provides superior 24-hour blood pressure control and proven cardiovascular outcomes 1, 2, 3
The use of chlorthalidone is preferred over HCTZ due to its greater 24-hour ambulatory blood pressure reduction, with the largest difference occurring overnight 1, 2, 3
Patients with resistant hypertension have occult volume expansion that responds primarily to increased diuretic use, and the current regimen lacks diuretic therapy, which is essential in resistant hypertension 1, 2, 3

The American College of Cardiology recommends avoiding the combination of diltiazem (non-dihydropyridine CCB) with metoprolol (beta-blocker) due to increased risk of bradycardia and heart block 5
The guideline-recommended triple therapy is ACE inhibitor + calcium channel blocker + thiazide diuretic, which can be achieved by adding chlorthalidone and discontinuing either diltiazem or metoprolol 1, 4, 3

The American Heart Association recommends checking serum potassium and creatinine 2-4 weeks after initiating diuretic therapy to detect hypokalemia or changes in renal function 5
Reinforcing sodium restriction to <2g/day can provide 5-10 mmHg systolic reduction, and encouraging weight loss if overweight, regular aerobic exercise, and alcohol limitation can provide additive blood pressure reductions of 10-20 mmHg 1

The American College of Cardiology recommends adding spironolactone 25-50mg daily as the fourth agent if blood pressure remains elevated despite optimized triple therapy (ACE inhibitor + CCB + thiazide) 1, 4
Spironolactone is the preferred fourth-line agent for resistant hypertension, providing additional blood pressure reductions when added to triple therapy 1, 4